These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1547574)

  • 41. Comparison of the Microgenics CEDIA heroin metabolite (6-AM) and the Roche Abuscreen ONLINE opiate immunoassays for the detection of heroin use in forensic urine samples.
    Holler JM; Bosy TZ; Klette KL; Wiegand R; Jemionek J; Jacobs A
    J Anal Toxicol; 2004 Sep; 28(6):489-93. PubMed ID: 15516301
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Application of drug testing using exhaled breath for compliance monitoring of drug addicts in treatment.
    Carlsson S; Olsson R; Lindkvist I; Beck O
    Scand J Clin Lab Invest; 2015 Apr; 75(2):156-61. PubMed ID: 25562730
    [TBL] [Abstract][Full Text] [Related]  

  • 43. False-positive buprenorphine EIA urine toxicology results due to high dose morphine: a case report.
    Tenore PL
    J Addict Dis; 2012; 31(4):329-31. PubMed ID: 23244551
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Urine specimen detection of concurrent nonprescribed medicinal and illicit drug use in patients prescribed buprenorphine.
    Guo AY; Ma JD; Best BM; Atayee RS
    J Anal Toxicol; 2013; 37(9):636-41. PubMed ID: 24080973
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analysis of buprenorphine in urine specimens.
    Debrabandere L; Van Boven M; Daenens P
    J Forensic Sci; 1992 Jan; 37(1):82-9. PubMed ID: 1545216
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Measurement of creatinine in urine screening for drugs of abuse.
    Simpson D; Jarvie DR; Moore FM
    Clin Chem; 1993 Apr; 39(4):698-9. PubMed ID: 8472375
    [No Abstract]   [Full Text] [Related]  

  • 47. Hydrolysis of conjugated metabolites of buprenorphine II. The quantitative enzymatic hydrolysis of norbuprenorphine-3-beta-D-glucuronide in human urine.
    Elsohly MA; Gul W; Feng S; Murphy TP
    J Anal Toxicol; 2005 Sep; 29(6):570-3. PubMed ID: 16168181
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Commonly used fluoroquinolones cross-react with urine drug screens for opiates, buprenorphine, and amphetamines.
    Colby JM; Patel PC; Fu DY; Rutherford NJ
    Clin Biochem; 2019 Jun; 68():50-54. PubMed ID: 30991036
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical Interpretation of Urine Drug Tests: What Clinicians Need to Know About Urine Drug Screens.
    Moeller KE; Kissack JC; Atayee RS; Lee KC
    Mayo Clin Proc; 2017 May; 92(5):774-796. PubMed ID: 28325505
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multifocal bone infarcts and buprenorphine: association or coincidence?
    Laroche M; Brouchet A; Mazières B
    J Rheumatol; 2009 Oct; 36(10):2369-70. PubMed ID: 19820227
    [No Abstract]   [Full Text] [Related]  

  • 51. An investigation into the extent of possible dilution of specimens received for urinary drugs of abuse screening.
    George S; Braithwaite RA
    Addiction; 1995 Jul; 90(7):967-70. PubMed ID: 7663318
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of an Automated Reader and Color Interpretation-Based Immunoassays for Multiplexed Drug-of-Abuse Testing in Urine.
    Kim SY; Kim H; Park Y; Lim J; Kim J; Koo SH; Kwon GC
    J Anal Toxicol; 2017 Jun; 41(5):412-420. PubMed ID: 28201761
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High buprenorphine-related mortality is persistent in Finland.
    Kriikku P; Häkkinen M; Ojanperä I
    Forensic Sci Int; 2018 Oct; 291():76-82. PubMed ID: 30170272
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Parenteral buprenorphine-naloxone abuse is a major cause of fatal buprenorphine-related poisoning.
    Häkkinen M; Heikman P; Ojanperä I
    Forensic Sci Int; 2013 Oct; 232(1-3):11-5. PubMed ID: 24053859
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Determination of buprenorphine in urine].
    Hegstad S; Christophersen AS; Khiabani HZ
    Tidsskr Nor Laegeforen; 2008 Jan; 128(2):184-5. PubMed ID: 18202730
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of buprenorphine CEDIA assay versus GC-MS and ELISA using urine samples from patients in substitution treatment.
    Böttcher M; Beck O
    J Anal Toxicol; 2005; 29(8):769-76. PubMed ID: 16356333
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cross-reactivity of the CEDIA buprenorphine assay with opiates: an Austrian phenomenon?
    Pavlic M; Libiseller K; Grubwieser P; Rabl W
    Int J Legal Med; 2005 Nov; 119(6):378-81. PubMed ID: 15834736
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Urine Spiking in a Pain Medicine Clinic: An Attempt to Simulate Adherence.
    Lee D; Bazydlo LA; Reisfield GM; Goldberger BA
    Pain Med; 2015 Jul; 16(7):1449-51. PubMed ID: 25522892
    [No Abstract]   [Full Text] [Related]  

  • 59. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS).
    Manchikanti L; Malla Y; Wargo BW; Cash KA; Pampati V; Damron KS; McManus CD; Brandon DE
    Pain Physician; 2010; 13(1):E1-E22. PubMed ID: 20119473
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Substances of abuse in urine samples].
    Mørland J
    Tidsskr Nor Laegeforen; 2011 Mar; 131(6):560. PubMed ID: 21423299
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.